STOCK TITAN
  1. Home
  2. News
  3. VOR

Vor Biopharma Inc - VOR STOCK NEWS

Welcome to our dedicated news page for Vor Biopharma (Ticker: VOR), a resource for investors and traders seeking the latest updates and insights on Vor Biopharma.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Vor Biopharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Vor Biopharma's position in the market.

News
Vor Bio to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Vor Bio (Nasdaq: VOR) to participate in upcoming investor conferences to discuss developments in cell and genome engineering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.17%
Tags
conferences
-
News
Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
Rhea-AI Summary
Vor Bio (Nasdaq: VOR) reports positive financial results for Q4 2023 and full year 2023, with a cash position of $137.2 million funding operations into the second half of 2025. Fast Track and Orphan Drug Designation granted to VCAR33ALLO by FDA. Multiple patients to be dosed with VCAR33ALLO in 2024. Trem-cel and VCAR33ALLO clinical trial data expected in the second half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.89%
Tags
earnings
-
News
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Vor Bio (Nasdaq: VOR) granted stock options and RSUs to two new employees as inducements for employment. The options have a ten-year term with an exercise price of $2.27 per share, vesting over four years, while the RSUs also vest over four years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.28%
Tags
none
News
Vor Bio to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Vor Bio (Nasdaq: VOR) will participate in investor conferences including Barclays 26th Annual Global Healthcare Conference and H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference. Fireside chats will be held on March 12 and March 26, 2024, respectively.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.32%
Tags
conferences
-
News
Vor Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Rhea-AI Summary
Vor Bio (Nasdaq: VOR) will participate in a fireside chat and host virtual 1x1 investor meetings at the Oppenheimer 34th Annual Healthcare Life Sciences Conference. The fireside chat will take place on February 14, 2024, at 10:00 am ET, and will be available for live webcast and archived replay on the company's website. This event presents an opportunity for investors to engage with Vor Bio and gain insights into its clinical-stage cell and genome engineering endeavors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.29%
Tags
conferences
-
News
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Vor Bio (Nasdaq: VOR) granted stock options and restricted stock units to five newly hired employees as material inducements to employment with a ten-year term and an exercise price of $2.415 per share. The options will vest over a four-year period, and the RSUs will vest over a four-year period, subject to the employee’s continued employment with Vor Bio on such vesting dates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
Vor Bio Doses First AML Patient with VCAR33 (ALLO) and Provides Corporate Update
Rhea-AI Summary
Vor Bio (Nasdaq: VOR) announces dosing of first patient in VBP301 clinical trial for VCAR33ALLO, extending cash runway into second half of 2025. Initial data expected in second half of 2024. The company aims to provide a healthy transplant donor-derived CAR-T developmental therapy for AML patients, with potential to reduce relapse risk or treat evidence of relapse.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.39%
Tags
none
-
News
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Vor Bio (Nasdaq: VOR) granted stock options and restricted stock units to a newly hired employee as material inducements to employment with a ten-year term and an exercise price of $2.29 per share. The options and RSUs will vest over a four-year period, subject to the employee’s continued employment with Vor Bio on such vesting dates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.37%
Tags
none
-
News
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Vor Bio (Nasdaq: VOR) Grants Stock Options and RSUs to Newly Hired Employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
Vor Bio to Participate in the JMP Securities Hematology and Oncology Summit
Rhea-AI Summary
Vor Bio (VOR) to Participate in Fireside Chat at JMP Securities Hematology and Oncology Summit
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.17%
Tags
conferences
Stock VOR logo
Vor Biopharma Inc

Nasdaq:VOR

VOR Rankings

#4146 Ranked by Market Cap
#4827 Ranked by Stock Gains
N/A Ranked by Dividends

VOR Stock Data

129.61M
31.89M
1.25%
88.44%
4.76%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
Cambridge

About VOR

vor biopharma is pioneering engineered hematopoietic stem cells (ehscs) to dramatically change the treatment paradigm for hematological cancers. vor’s ehscs are designed to generate healthy, fully functional cells with specific advantageous modifications, for example to protect the blood and bone marrow from the toxic effects of antigen-targeted therapies, protecting healthy cells from depletion but leaving tumor cells vulnerable. vor’s platform could potentially be used to change the treatment paradigm of both hematopoietic stem cell transplants and antigen-targeted therapies such as antibody drug conjugates, bispecific antibodies and car-t cell treatments. a proof-of-concept study for vor’s lead program has been published in proceedings of the national academy of sciences. vor is based in cambridge, mass. and has a broad intellectual property base including in-licenses from columbia university, where foundational work was conducted by inventor and vor scientific board chair siddhar